WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

This group comprises all hormonal preparations for systemic use, except:
- Insulins, see A10.
- Anabolic steroids, see A14.
- Catecholamines, see C01C and R03C.
- Sex hormones, see G03.
- Sex hormones used in treatment of neoplastic diseases, see L02.
- Metreleptin used for treatment of complications of leptin deficiency in patients with generalised lipodystrophy is classified in A16AA.

The DDDs are generally based on the treatment or diagnosis of endocrine disorders.


H03 THYROID THERAPY
H03A THYROID PREPARATIONS

This group comprises thyroid extracts and synthetic analogues used in the treatment of hypothyrosis.

The DDDs are based on the treatment of hypothyrosis.


H03AA Thyroid hormones

This group comprises natural and synthetic thyroid hormones. Combinations of levothyroxine and liothyronine are classified at a separate 5th level: H03AA03.
Liothyronine hydrochloride is classified in H03AA02.


    ATC code  Name  DDD  U Adm.R Note
    H03AA02 liothyronine sodium 60 mcg 
    60 mcg 

List of abbreviations

Last updated: 2024-01-26